For the third quarter of 2010, the company posted a net income of $155m, compared to $326m for the same period in 2009.
McKesson’s operating income for the third quarter of 2010 was $307m, compared to $509m for the same period in 2009.
For the nine months ended 31 December 2010, the company posted a net income of $780m, compared to $915m in prior year.
Revenues for the nine months of 2010 were $83.23m, compared to $82.05m for the same period in 2009.
Operating income was $1.19bn, compared to $1.43bn in the same period of 2009.
McKesson chairman and CEO John Hammergren said McKesson continued to demonstrate solid execution in the third quarter.
"Based on our results for the first nine months, we are raising our previous outlook for the fiscal year ending March 31, 2011, and now expect that McKesson should earn between $4.82 and $5.02 per diluted share from continuing operations, excluding adjustments to the litigation reserves and estimated full-year US Oncology transaction expenses of approximately 15 cents per diluted share," Hammergren said.